Combined transarterial chemoembolization and tislelizumab for patients with unresectable hepatocellular carcinoma

Figure 1 Flowchart showing the detailed patients screening process of this study. HCC: Hepatocellular carcinoma; TACE: Transarterial chemoembolization; ECOG-PS: Eastern Cooperative Oncology Group Performance Status.

Figure 2 Patient overall survival. A: Overall survival (OS); B-F: OS comparison by vascular invasion status (B), immunotherapy sequence (C), prior transarterial chemoembolization (D), combined targeted therapy (E) and treatment line of immunotherapy (F). OS: Overall survival; TACE: Transarterial chemoembolization.

Figure 3 Patient progression-free survival. A: Overall progression-free survival (PFS); B-F: PFS comparison by vascular invasion status (B), immunotherapy sequence (C), prior transarterial chemoembolization ((D), combined targeted therapy (E) and treatment line of immunotherapy (F). PFS: Progression-free survival; TACE: Transarterial chemoembolization.